News

Wednesday January 31, 2024

Clinical development update

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Clinical development update Positive Results from XF-73 Dermal Safety Study XF-73 Dermal to be progressed towards clinical evaluation for the treatment of […]

Monday January 22, 2024

Appointment of Nominated Adviser and Sole Broker

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Appointment of Nominated Adviser and Sole Broker Brighton, United Kingdom ‐ 22 January 2024 ‐ Destiny Pharma (AIM: DEST), a clinical stage […]

Thursday January 4, 2024

Year End Business Update

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Year End Business Update Brighton, United Kingdom – 4 January 2024 – Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the […]

Tuesday October 17, 2023

XF Pipeline Update Meeting

Destiny Pharma plc (“Destiny Pharma” or “the Company”) XF Pipeline Update Meeting with Leading Experts and New Microbiological Data on XF-73 Brighton, United Kingdom – 17 October 2023 – Destiny […]

Tuesday October 17, 2023

Publication of new microbiological data for XF-73

Destiny Pharma plc (“Destiny Pharma” or “the Company”) New publication shows XF‐73 drug potent against 2,527 Staphylococcus isolates Largest study of its kind to date demonstrates effectiveness of XF‐73 against […]

Tuesday July 25, 2023

Appointment of new Chairman

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Appointment of new Chairman  Brighton, United Kingdom – 25 July 2023: Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on […]

Tuesday May 2, 2023

Positive results from SPOR-COV® research

Destiny Pharma and SporeGen® announce update from research collaboration under Innovate UK grant award to develop a biotherapeutic treatment (SPOR-COV®) for COVID-19 and Influenza Positive results from testing SPOR-COV in […]

Wednesday April 26, 2023

Posting of Annual Report and Accounts, and Notice of AGM

Destiny Pharma plc (“Destiny Pharma” or “the Company”)  Posting of Annual Report and Accounts, and Notice of AGM   Brighton, United Kingdom – 26 April 2023 – Destiny Pharma plc (AIM: DEST) […]

Thursday April 13, 2023

Audited results for year ended 31 December 2022

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Audited results for the year ended 31 December 2022 Exclusive North American partnering deal worth up to $570m plus royalties secured for […]

Tuesday April 4, 2023

Landmark data published on NTCD-M3

Destiny Pharma plc(“Destiny Pharma” or “the Company”) Landmark data published on successful NTCD‐M3gut colonisation after fidaxomicin administration Brighton, United Kingdom ‐ 4 April 2023 ‐ Destiny Pharma (AIM: DEST), a clinical stage innovative […]